<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: Zenhancer Filings -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: www.zenhancer.com -->
    <!-- Field: Doc-Info; Name: Source; Value: C:\Users\adim\Desktop\111111111111\TAPIMMUNE INC\Conversion\TAPIMMUNE INC.xfr; Date: 2015%2D04%2D15T12:18:33 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:tpiv="http://tapimmune.com/20141231">
    <link:schemaRef xlink:href="tpiv-20141231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_FairValueHedging1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">tpiv:FairValueHedging1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ConvertibleNotesPayableMember10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable3Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable4Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable5Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable6Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable12Member10354425">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable16Member10354441">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable18Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable19Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable21Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueHedgingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:OIfficerAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OIfficerAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:OIfficerAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesAWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesBWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesCWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesDWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchNineTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_MarchNineTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchNineTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Patients">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>tpiv:Patients</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>tpiv:Number</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1465712</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">20318815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1465712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">20318815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-8768003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-6042522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">46715500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-55426635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-58334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-1023636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">20319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">43912427</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">85265776</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-49894083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-86309731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-61648</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1250000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1250000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">48589</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">33839</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">141944</us-gaap:Cash>
    <tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">210000</tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4349428</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1836</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4347592</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2015-04-10" unitRef="Shares" decimals="INF">32638810</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">77032</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">224448</us-gaap:AssetsCurrent>
    <us-gaap:PostconfirmationDeferredFinancingCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">13439</us-gaap:PostconfirmationDeferredFinancingCosts>
    <us-gaap:PostconfirmationDeferredFinancingCosts contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15004</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">82504</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">8845035</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1248084</us-gaap:LiabilitiesCurrent>
    <us-gaap:LoansPayable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">42200</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-582300</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">77032</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">224448</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-58334</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-55426635</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-86309731</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">46715500</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">85265776</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1466</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">20319</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">697634</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">189000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1966683</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3181927</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5896</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-52976</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AccretionOfDiscount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1110831</us-gaap:AccretionOfDiscount>
    <us-gaap:AccretionOfDiscount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">492296</us-gaap:AccretionOfDiscount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1546257</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">581</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3314</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5529238</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30824762</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-4.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">-2.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">1136115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">15465213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5532552</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30883096</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">132093</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1391123</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2560045</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-26884231</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">76367</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1835315</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-145199</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">24013</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-67500</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-694583</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-2187145</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">32200</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1877500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">709333</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2280500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">14750</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">93355</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">369000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">525000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">645562</tpiv:NoncashInterestAndFinanceCharges>
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">83247</tpiv:NoncashInterestAndFinanceCharges>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">558000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2415000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42000</us-gaap:IncreaseDecreaseInNotesPayableRelatedParties>
    <us-gaap:SharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1465712</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">764029</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20318816</us-gaap:SharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">412047</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1477587</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">412</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1477175</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">46840</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">46840</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">31891</tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements>
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">31891</tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements>
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">264649</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreements>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1211627</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">265</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1211362</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-11300</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-11300</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3500</tpiv:IssuedAtFairValuePursuantToServiceAgreements>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">38936</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">38932</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2500</tpiv:SharesIssuedForDirectorCompensation>
    <tpiv:SharesIssuedForDirectorCompensation contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">811000</tpiv:SharesIssuedForDirectorCompensation>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8176</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1391123</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">811</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8173</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1390312</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:NoncashExerciseOfWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">18986</tpiv:NoncashExerciseOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5532552</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30883096</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5532552</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-30883096</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStock contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14048701</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStock>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30951078</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14049</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30937029</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStock contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1836361</tpiv:ConversionOfAccountsPayableToCommonStock>
    <tpiv:PrivatePlacementNetOfFindersFee contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2157042</tpiv:PrivatePlacementNetOfFindersFee>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1877500</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2157</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1875343</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3314</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">3314</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">58334</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">387500</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">387500</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-492365</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-492365</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:LoansAndLeasesReceivableCommercial contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-277942</us-gaap:LoansAndLeasesReceivableCommercial>
    <us-gaap:LoansAndLeasesReceivableCommercial contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-52942</us-gaap:LoansAndLeasesReceivableCommercial>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3778401</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">693362</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <dei:EntityRegistrantName contextRef="From2014-01-01to2014-12-31">TAPIMMUNE INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2014-01-01to2014-12-31">0001094038</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2014-01-01to2014-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2014-01-01to2014-12-31">2014-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2014-01-01to2014-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2014-01-01to2014-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2014-01-01to2014-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2014-01-01to2014-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2014-01-01to2014-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2014-01-01to2014-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2014-01-01to2014-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2014-01-01to2014-12-31">2014</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat contextRef="AsOf2014-06-30" unitRef="USD" decimals="0">30929000</dei:EntityPublicFloat>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3161977</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">369346</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2664317</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-3370927</us-gaap:OperatingIncomeLoss>
    <tpiv:LossOnLawsuit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-103950</tpiv:LossOnLawsuit>
    <tpiv:LossOnLawsuit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:InterestAndFinanceCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-645562</tpiv:InterestAndFinanceCharges>
    <tpiv:InterestAndFinanceCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-83247</tpiv:InterestAndFinanceCharges>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1546257</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-581</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <tpiv:AccretionOfInterestOnConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1110831</tpiv:AccretionOfInterestOnConvertibleDebt>
    <tpiv:AccretionOfInterestOnConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">492296</tpiv:AccretionOfInterestOnConvertibleDebt>
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2560045</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">26884231</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">20000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-15000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1450083</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">620826</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1348663</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">201334</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">68448</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">220290</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">558032</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3778401</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">693362</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">492365</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="AsOf2014-12-31" unitRef="Pure" decimals="INF">0.15</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-03-31">P2M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-04-01to2014-06-30">P22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">712000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">708000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">4000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember">P10M6D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember">P2Y9M11D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember">P1Y2M19D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember">P3Y6M11D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0013</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0078</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0025</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.011</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">1.99</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">1.559</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">1.99</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="0">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="0">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9415</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="0">9415</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">9415</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">140000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">583000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">868000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">977000</us-gaap:LiabilitiesFairValueDisclosure>
    <tpiv:AdditionsDuringYear contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">206000</tpiv:AdditionsDuringYear>
    <tpiv:AdditionsDuringYear contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">811000</tpiv:AdditionsDuringYear>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">-1096000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">-714000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">131000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">-1043000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">-131000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">140000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">583000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">9000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">--12-23</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">--02-24</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">--04-04</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">--06-06</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">--08-12</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">--08-20</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">--10-15</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">--11-20</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">--12-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">--01-05</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">--01-31</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">--02-27</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">--04-02</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">--04-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">--05-02</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">--05-05</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">--05-14</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">--06-27</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">--06-19</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">--07-12</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">--10-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">--11-01</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">--12-19</tpiv:IssueDates>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">--06-23</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">--02-24</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">--04-04</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">--06-06</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">--11-12</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">--08-20</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">--10-15</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">--11-20</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">--12-14</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">--02-27</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">--06-02</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">--12-18</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">--07-05</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">--05-14</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">--06-27</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">--06-19</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">--07-12</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">--04-18</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">--05-01</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">--06-19</tpiv:MaturityDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389" unitRef="Pure" decimals="INF">0.09</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member"> &#9;Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember"> &#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327"> &#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member"> &#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member"> &#9;Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">Variable at $12.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389"> Fixed at $10.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">Fixed at $8.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">Fixed at $4.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">Variable at $3.44</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">Fixed at $6.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">Fixed at $3.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_us-gaap_ConvertibleNotesPayableMember10354410" unitRef="USD" decimals="0">980858</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable1Member" unitRef="USD" decimals="0">215000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable2Member" unitRef="USD" decimals="0">30000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable3Member10354410" unitRef="USD" decimals="0">27500</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable4Member10354410" unitRef="USD" decimals="0">20000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable5Member10354410" unitRef="USD" decimals="0">340000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable6Member10354410" unitRef="USD" decimals="0">10748</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable7Member" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable8Member" unitRef="USD" decimals="0">452729</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable9Member" unitRef="USD" decimals="0">24135</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable10Member" unitRef="USD" decimals="0">58500</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable11Member" unitRef="USD" decimals="0">80967</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable12Member10354425" unitRef="USD" decimals="0">31688</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable13Member" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable14Member" unitRef="USD" decimals="0">45000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable15Member" unitRef="USD" decimals="0">126000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable16Member10354441" unitRef="USD" decimals="0">37620</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable17Member" unitRef="USD" decimals="0">32000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable18Member" unitRef="USD" decimals="0">96800</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable19Member" unitRef="USD" decimals="0">94444</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable20Member" unitRef="USD" decimals="0">80000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable21Member" unitRef="USD" decimals="0">277222</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable22Member" unitRef="USD" decimals="0">536400</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <tpiv:TotalConvertibleNotes contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3697611</tpiv:TotalConvertibleNotes>
    <tpiv:TotalConvertibleNotes contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:UnamortizedNoteDiscount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-535634</tpiv:UnamortizedNoteDiscount>
    <tpiv:UnamortizedNoteDiscount contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:TotalOnBalanceSheet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3161977</tpiv:TotalOnBalanceSheet>
    <tpiv:TotalOnBalanceSheet contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FederalHomeLoanBankAdvancesDiscount contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">42200</us-gaap:FederalHomeLoanBankAdvancesDiscount>
    <us-gaap:FederalHomeLoanBankAdvancesDiscount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:FederalHomeLoanBankAdvancesDiscount>
    <tpiv:InvestorsConverted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">37000</tpiv:InvestorsConverted>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">5200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">12000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <tpiv:OutstandingPrincipalAmount contextRef="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">210000</tpiv:OutstandingPrincipalAmount>
    <tpiv:OutstandingPromissoryNotes contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">277942</tpiv:OutstandingPromissoryNotes>
    <tpiv:OutstandingPromissoryNotes contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">52942</tpiv:OutstandingPromissoryNotes>
    <tpiv:OutstandingPromissoryNotes contextRef="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">23000</tpiv:OutstandingPromissoryNotes>
    <tpiv:AmountOfPromissoryNotesRepaid contextRef="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">15000</tpiv:AmountOfPromissoryNotesRepaid>
    <tpiv:AmountOfPromissoryNotesRepaid contextRef="From2013-01-01to2013-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">0</tpiv:AmountOfPromissoryNotesRepaid>
    <us-gaap:NotesPayable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">369000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:NotesPayable>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1250000</tpiv:PreferredStock>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:PreferredStock>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">265000</tpiv:PreferredStock>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">811000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">100000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">1886792</us-gaap:CommonStockDividendsShares>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">954000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">105000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">5250</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:ManagementFeeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">132093</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15000</us-gaap:ManagementFeeExpense>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1321000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1265000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1321000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1265000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1321000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1265000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">9174000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10433000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tpiv:DeferredTaxStockBasedCompensation contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1866000</tpiv:DeferredTaxStockBasedCompensation>
    <tpiv:DeferredTaxStockBasedCompensation contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1871000</tpiv:DeferredTaxStockBasedCompensation>
    <tpiv:DeferredTaxTechnologyLicensingFee contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">167000</tpiv:DeferredTaxTechnologyLicensingFee>
    <tpiv:DeferredTaxTechnologyLicensingFee contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">167000</tpiv:DeferredTaxTechnologyLicensingFee>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">11207000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">12471000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-11207000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-12471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2415000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <tpiv:ConvertibleCommonStockSharesIssuedUponConversion contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">1836000</tpiv:ConvertibleCommonStockSharesIssuedUponConversion>
    <tpiv:TradingOfSharesAtFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4349000</tpiv:TradingOfSharesAtFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">14000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <tpiv:LossOnExtinguishment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1934000</tpiv:LossOnExtinguishment>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">738000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4116000</us-gaap:ProceedsFromConvertibleDebt>
    <tpiv:ConvertibleNotesNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">728000</tpiv:ConvertibleNotesNet>
    <tpiv:ConvertibleNotesNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">418000</tpiv:ConvertibleNotesNet>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30867</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="0">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-9415</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="0">-9415</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-9415</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">140504</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9415</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:NatureOfOperations contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;1:&amp;#9;Nature of Operations&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;TapImmune Inc. (the &amp;#147;Company&amp;#148;),&#13;a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development&#13;of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike&#13;other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates&#13;the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation&#13;in tumor cells allowing their recognition and killing by the immune system.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A Phase I study at the Mayo Clinic is currently&#13;evaluating the safety and immune responses of a set of proprietary HER2/neu antigens that will be part of the &amp;#34;Prime&amp;#34;&#13;for a HER2/neu breast cancer vaccine.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A second Phase I trial is underway at Mayo&#13;Clinic (&amp;#147;Mayo&amp;#148;) in Ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly&#13;50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy,&#13;leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of&#13;cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer&#13;patients newly diagnosed every year. These Folate Receptor Antigens are applicable to Ovarian and Triple Negative Breast Cancer.&#13;Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that&#13;it might be an ideal candidate for orphan drug status in these indications.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Phase II advancement will be assessed in&#13;the second quarter of 2015. TapImmune has an exclusive option to license this set of peptides after successful phase 1 trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, enhancing the visibility&#13;of cancer or infected cells to a patient&amp;#146;s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune&amp;#146;s&#13;PolyStart&amp;#153; nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic&#13;epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived&#13;Killer T-cell populations that then effectively seek out and work to destroy a patient&amp;#146;s cancer cells.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is also&#13;exploiting the emerging field of vaccinomics for the development of vaccines applicable to a broad patient population. TapImmune's&#13;immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These consolidated financial statements&#13;have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities&#13;in the normal course of business. As at December 31, 2014, the Company had a working capital deficiency and has incurred significant&#13;losses since inception in the development of its business. Further losses are anticipated raising substantial doubt as to the Company&amp;#146;s&#13;ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on raising additional&#13;capital to fund clinical trials, ongoing research and development, maintenance and protection of patents, accommodation from certain&#13;debt obligations and ultimately on generating future profitable operations. Planned expenditures relating to current and future&#13;clinical trials of the Company&amp;#146;s immunotherapy vaccine will require significant additional funding. The Company is dependent&#13;on future financings to fund ongoing research and development as well as working capital requirements. The Company&amp;#146;s future&#13;capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development&#13;programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections&#13;and the timing and costs of commercialization activities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management is addressing going concern&#13;remediation through seeking new sources of capital, restructuring and retiring debt through conversion to equity and debt settlement&#13;arrangements with creditors, cost reduction programs and seeking possible joint venture participation. Management&amp;#146;s plans&#13;are intended to return the Company to financial stability and improve continuing operations. The Company is continuing initiatives&#13;to raise capital through private placements, related party loans and other institutional sources to meet immediate working capital&#13;requirements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Historically the Company has raised capital&#13;through issuances of various financial instruments and the Company recently completed significant restructuring of outstanding&#13;debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress&#13;clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio&#13;and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for&#13;the Company over the next twelve months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There is no certainty that the Company&#13;will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;2:&amp;#9;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basis of Presentation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements are presented&#13;in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States&#13;of America (&amp;#147;GAAP&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Principles of Consolidation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements include the&#13;accounts of the Company and its wholly-owned subsidiaries GeneMax Pharmaceuticals Inc. (&amp;#147;GPI&amp;#148;) and GeneMax Pharmaceuticals&#13;Canada Inc. (&amp;#147;GPC&amp;#148;). All significant intercompany balances and transactions are eliminated upon consolidation. In the&#13;fourth quarter of fiscal 2014, the Company dissolved GPC and no longer has any Canadian subsidiary.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Preparation of the Company&amp;#146;s financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and&#13;disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&amp;#146;s&#13;estimates and assumptions include deferred taxes and related tax balances and disclosures, determining the fair value of stock-based&#13;compensation and stock based transactions, the fair value of the components of the convertible notes payable and accrued liabilities.&#13;Matters impacting the Company&amp;#146;s ability to continue as a going concern and contingencies also involve the use of estimates&#13;and assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of certain of the Company&amp;#146;s&#13;financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost&#13;because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a&#13;recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values.&#13;Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets&#13;and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated&#13;by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets&#13;or liabilities. Financial Instruments and Concentration of Credit Risk.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of cash, accounts payable,&#13;and other current monetary liabilities approximate their carrying values due to the immediate or short-term maturity of these financial&#13;instruments. The Company&amp;#146;s operations and financing activities are conducted primarily in United States dollars, and as a&#13;result the Company is not subject to significant exposure to market risks from changes in foreign currency rates. Unless otherwise&#13;noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from assets and&#13;liabilities classified as financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Prior Period Reclassifications&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior period amounts that were&#13;combined in the December 31, 2013 consolidated financial statements have been reclassified for comparability with the December&#13;31, 2014 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-Based Compensation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is measured at&#13;the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized&#13;as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized&#13;for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is&#13;determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&amp;#160;&amp;#151; The expected&#13;term of options represents the period that the Company&amp;#146;s stock-based awards are expected to be outstanding based on the simplified&#13;method, which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent&#13;remaining term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&amp;#160;&amp;#151; The&#13;Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable&#13;future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock&#13;options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred Financing Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company defers direct costs incurred&#13;in connection with the sale of common shares which are offset against the proceeds of the financing upon completion. Costs incurred&#13;in connection with convertible loans payable are deferred and amortized as a financing cost over the term of the convertible loans.&#13;Upon conversion of the loan, any unamortized amount of deferred financing costs will be charged to stockholders&amp;#146; equity as&#13;a cost of financing.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and Development Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has acquired development and&#13;marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may&#13;not have alternate future uses and therefore, have been expensed as incurred as research and development costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income Taxes&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the asset and liability&#13;method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax&#13;consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective&#13;tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable&#13;income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets&#13;and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances against deferred&#13;tax assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Derivative Liability&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates its convertible debt,&#13;options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives&#13;to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying&#13;amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the&#13;fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as&#13;either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is&#13;marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In circumstances where the embedded conversion&#13;option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the&#13;convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single,&#13;compound derivative instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The classification of financial instruments,&#13;including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting&#13;period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to&#13;liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified&#13;in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected&#13;within 12 months of the balance sheet date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In evaluating the application of ASC 815-40,&#13;management must determine whether an instrument (or an embedded feature) is indexed to the Company&amp;#146;s own stock. ASC 815-40-15&#13;provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature)&#13;is indexed to its own stock, including evaluating the instrument&amp;#146;s contingent exercise and settlement provisions. The application&#13;of ASC 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features&#13;and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain&#13;contingently puttable cash settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated the application&#13;ASC 480-10 &lt;i&gt;Distinguishing liabilities from equity&lt;/i&gt;, ASC 815-40 &lt;i&gt;Contracts in an Entity&amp;#146;s Own Equity&lt;/i&gt; and ASC 718-10&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt; to the issued and outstanding warrants to purchase common stock that were issued&#13;with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based&#13;on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet&#13;down protection feature available on the exercise price (Note 5) or a holder&amp;#146;s right to put the warrants back to the Company&#13;for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25,&#13;the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value,&#13;with changes in the values reflected in the Statements of Operations as &amp;#147;Changes in fair value of derivative liabilities&amp;#148;.&#13;The fair value of the share purchase warrants are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; warrants&amp;#146;&#13;and the fair value of the conversion options are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; conversion&#13;option&amp;#146;.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Loss per Common Share&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per share is computed by dividing loss attributable&#13;to common stockholders by the weighted average number of common shares outstanding for the period. If applicable, diluted earnings&#13;per share reflect the potential dilution of securities that could share in the earnings (loss) of the Company. The common shares&#13;potentially issuable on conversion of outstanding convertible debentures, warrants and stock options are anti-dilutive and have&#13;not been included in the calculation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Net Loss per Share Applicable to Common Stockholders&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options, warrants, and convertible debt outstanding were all&#13;considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities were not included in the diluted net&#13;loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;2,556,133&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;25,168&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;103,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;124,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;738,760&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Excluded potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;2,724,847&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;953,642&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Update No. 2014-10,&#13;&lt;i&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to&#13;Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/i&gt; removes all incremental financial reporting requirements for&#13;development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the&#13;period from inception to the end of the current period. The update is effective for the first annual period beginning after December&#13;15, 2014. Early adoption is permitted, and the Company has adopted this change effective with its form 10-Q filing for the period&#13;ending September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements&amp;#151;Going Concern&#13;(Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. The amendments&#13;in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods&#13;thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;3:&amp;#9;accounts payable and accrued liabilities&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounts Payable and Accrued Liabilities&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;December 31, 2014 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;December 31, 2013 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;Trade accounts payable &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;620,826 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,450,083 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;Share-settled debt&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;1,348,663&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;Accrued liabilities &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;68,448 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;201,334 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;Employee payroll and severance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;220,290 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;Accrued interest &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,088 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;558,032 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;693,362 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;3,778,401&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During fiscal 2014 the Company converted&#13;$2,415,000 accounts payable and accrued liabilities into 1,836,000 shares of common stock. The fair value of the shares, based&#13;on the trading price of the stock on the date of conversion, was $4,349,000 and the Company recorded a loss on extinguishment of&#13;$1,934,000.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;4:&amp;#9;Research Agreements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Crucell Holland B.V. (&amp;#147;Crucell&amp;#148;) &amp;#150; Research&#13;License and Option Agreement&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective August 7, 2003, Crucell and the&#13;Company&amp;#146;s subsidiary GPI entered into a five-year research license and option agreement. In addition, retroactively effective&#13;August 7, 2008, the Company negotiated an amended license agreement for the use of Crucell&amp;#146;s adenovirus technology. The Company&#13;was required to make annual license payments on the anniversary of the effective date for the three year term equal to $91,000&#13;per annum for three years through December 2011. As of December 31, 2013 and 2014, the Company accrued $492,365 under the amended&#13;agreement, inclusive of 15% interest on outstanding amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has not made use of the Crucell&#13;technology in its current work and has not asked for nor received any work product. Management hopes to settle the outstanding&#13;amounts with Crucell in 2015 and formally terminate the research license.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;/font&gt;NOTE&#13;5:&amp;#9;DERIVATIVE LIABILITY &lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During 2014 the Company entered into numerous&#13;extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion&#13;options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations.&#13;The inputs utilized in the final mark to market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter ending June 30, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Total&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Dividend yield (per share)&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Strike price&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;1.027&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.88&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Volatility (annual)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Contractual term (years)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.06&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Fair value of Conversion Option at extinguishment&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;708,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;712,000 &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of quantitative information with&#13;respect to valuation methodology and significant unobservable inputs used for the Company&amp;#146;s common stock purchase warrants&#13;that are categorized within Level 3 of the fair value hierarchy for the years ended 2014 and 2013 is as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Share purchase warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.85 to 2.78&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.13% to 0.78%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;1.22 to 3.53&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.25% to 1.10%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;155.90% to 190.68%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The foregoing assumptions are recalculated&#13;every reporting period and are subject to change based primarily on management&amp;#146;s assessment of the probability of the events&#13;described occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Financial Assets and Liabilities Measured&#13;at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets and liabilities measured&#13;at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &amp;#150; warrants&#13;and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2014 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2013&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no transfers between Level 1,&#13;2 or 3 during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents changes in&#13;Level 3 liabilities measured at fair value for the year ended December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 34%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 40%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&amp;#160;Derivative liability &amp;#150; conversion option &lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Derivative liability &amp;#150; warrants&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; January 1, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$868,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$977,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;811,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;206,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,096,000)&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,043,000)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$583,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$140,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Gain on settlement of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(714,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of conversion option liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;131,000&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(131,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 9,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation of warrants is subjective&#13;and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility&#13;of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield.&#13;Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle&#13;the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial&#13;statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised,&#13;expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair&#13;value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The net cash settlement value at the time&#13;of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following&#13;inputs at that time: the consideration value per share of the Company&amp;#146;s common stock, the volatility of the Company&amp;#146;s&#13;common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U.S. Treasury security&#13;yields, and the Company&amp;#146;s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100%&#13;and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 8:&amp;#9;PROMISSORY&#13;NOTES, RELATED PARTY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has outstanding promissory notes in the amount of $52,942 (December 31, 2013 - $277,942), of which $23,000 of promissory&#13;notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment&#13;terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2014, a note holder converted outstanding principal of $210,000 and accrued interest of $12,000 into&#13;preferred stock which was immediately converted into common shares (see note 6).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2014, $15,000 (2013 - $nil) of the promissory notes were repaid to an officer and director of the&#13;Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE&#13;9:&amp;#9;DUE TO RELATED PARTIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2014 the Company has outstanding promissory notes in the amount of $nil (December 31, 2013 - $369,000).&#13;During the fiscal year 2014, the related parties converted the notes of $369,000 into preferred stock which was immediately converted&#13;into common stock (See note 6).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;b&gt;Note&#13;12:&amp;#9;CONTINGENCIES AND COMMITMENTs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingencies:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Consultant&#13;Litigation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2012, the Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity&#13;of the services provided and initially were able to delay the sale of the contested shares. The Company was not successful in&#13;recovering the contested shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as&#13;a result of the contesting of the issuance of the shares has been filed in the Supreme Court of New York. The claim is for damages&#13;on the difference between market price at the time the Company was able to delay the sale of his shares and the market price at&#13;the time of the sale of all of his shares. As the result of a judicial decision in New York the consultant received a bond payment&#13;of approximately $100,000 that the Company had used to secure a temporary restraining order against the issuance of stock to him.&#13;Following hearings at the International Arbitration Tribunal held in New York on&amp;#160;May 13-16&amp;#160;the arbitrator ordered (on&#13;July 18, 2014) the consultant to pay Tapimmune $196,204 plus 9% interest from the date of the award. &lt;font style="background-color: white"&gt;The&#13;Company is attempting to collect the award from Mr. Gardner.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;law firm that we used to pursue the Gardner Action was awarded a judgment against us for $210,255 of unpaid legal fees (&amp;#147;G&amp;#38;S&#13;Judgment&amp;#148;). Shareholders of the Company acquired the G&amp;#38;S Judgment in full, converted that Judgment into preferred shares&#13;of the Company (which in turn converted into common stock) and subsequently released the Company from any liability related thereto.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;July 18, 2014, the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the&#13;matter of TapImmune Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This&#13;award stemmed from the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found&#13;that we were fraudulently induced into entering said agreement through &amp;#147;1) misrepresentations as to what he would or could&#13;do for the Company, including raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining&#13;financing for TapImmune&amp;#148; among other reasons. We are attempting to collect the award from Mr. Gardner.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;One&#13;of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them.&#13;We intend on settling that matter in the second quarter of 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;13:&amp;#9;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On January 12, 2015, the Company entered into a Securities Purchase Agreement with certain accredited&#13;investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000,&#13;net of finders&amp;#146; fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company&amp;#146;s&#13;Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share&#13;of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share&#13;of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively,&#13;the &amp;#147;January 2015 Warrants&amp;#148;). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B&#13;warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with&#13;a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are&#13;exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25&#13;per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series&#13;C warrants are exercised.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Pursuant to a placement agent&#13;agreement, the Company agreed to issue warrants to purchase an aggregate of up to 5% of the aggregate number of shares of common&#13;stock sold in the offering to the placement agents. The placement agent warrants have substantially the same terms as the January&#13;2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 17.85pt"&gt;&lt;/td&gt;&lt;td style="width: 17.85pt"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 9, 2015, the Company entered into a Securities Purchase Agreement with certain accredited&#13;investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000,&#13;net of finders&amp;#146; fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company&amp;#146;s&#13;Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share&#13;of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share&#13;of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively,&#13;the &amp;#147;March 2015 Warrants&amp;#148;). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"&gt;Pursuant to a placement agent&#13;agreement, the Company agreed to issue warrants to purchase an aggregate of up to 2.5% of the aggregate number of shares of common&#13;stock sold in the offering to the placement agents. The placement agent warrants have substantially the same terms as the March&#13;2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <tpiv:NetLossPerShareApplicableToCommonStockholdersPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Net Loss per Share Applicable to Common Stockholders&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options, warrants, and convertible debt outstanding were all&#13;considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities were not included in the diluted net&#13;loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;2,556,133&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;25,168&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;103,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;124,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;738,760&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Excluded potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;2,724,847&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;953,642&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:NetLossPerShareApplicableToCommonStockholdersPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Update No. 2014-10,&#13;&lt;i&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to&#13;Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/i&gt; removes all incremental financial reporting requirements for&#13;development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the&#13;period from inception to the end of the current period. The update is effective for the first annual period beginning after December&#13;15, 2014. Early adoption is permitted, and the Company has adopted this change effective with its form 10-Q filing for the period&#13;ending September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements&amp;#151;Going Concern&#13;(Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. The amendments&#13;in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods&#13;thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Loss per Common Share&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per share is computed by dividing loss attributable&#13;to common stockholders by the weighted average number of common shares outstanding for the period. If applicable, diluted earnings&#13;per share reflect the potential dilution of securities that could share in the earnings (loss) of the Company. The common shares&#13;potentially issuable on conversion of outstanding convertible debentures, warrants and stock options are anti-dilutive and have&#13;not been included in the calculation.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Derivative Liability&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates its convertible debt,&#13;options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives&#13;to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying&#13;amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the&#13;fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as&#13;either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is&#13;marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In circumstances where the embedded conversion&#13;option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the&#13;convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single,&#13;compound derivative instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The classification of financial instruments,&#13;including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting&#13;period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to&#13;liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified&#13;in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected&#13;within 12 months of the balance sheet date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In evaluating the application of ASC 815-40,&#13;management must determine whether an instrument (or an embedded feature) is indexed to the Company&amp;#146;s own stock. ASC 815-40-15&#13;provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature)&#13;is indexed to its own stock, including evaluating the instrument&amp;#146;s contingent exercise and settlement provisions. The application&#13;of ASC 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features&#13;and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain&#13;contingently puttable cash settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated the application&#13;ASC 480-10 &lt;i&gt;Distinguishing liabilities from equity&lt;/i&gt;, ASC 815-40 &lt;i&gt;Contracts in an Entity&amp;#146;s Own Equity&lt;/i&gt; and ASC 718-10&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt; to the issued and outstanding warrants to purchase common stock that were issued&#13;with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based&#13;on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet&#13;down protection feature available on the exercise price (Note 5) or a holder&amp;#146;s right to put the warrants back to the Company&#13;for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25,&#13;the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value,&#13;with changes in the values reflected in the Statements of Operations as &amp;#147;Changes in fair value of derivative liabilities&amp;#148;.&#13;The fair value of the share purchase warrants are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; warrants&amp;#146;&#13;and the fair value of the conversion options are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; conversion&#13;option&amp;#146;.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income Taxes&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the asset and liability&#13;method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax&#13;consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective&#13;tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable&#13;income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets&#13;and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances against deferred&#13;tax assets.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and Development Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has acquired development and&#13;marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may&#13;not have alternate future uses and therefore, have been expensed as incurred as research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred Financing Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company defers direct costs incurred&#13;in connection with the sale of common shares which are offset against the proceeds of the financing upon completion. Costs incurred&#13;in connection with convertible loans payable are deferred and amortized as a financing cost over the term of the convertible loans.&#13;Upon conversion of the loan, any unamortized amount of deferred financing costs will be charged to stockholders&amp;#146; equity as&#13;a cost of financing.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-Based Compensation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is measured at&#13;the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized&#13;as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized&#13;for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is&#13;determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&amp;#160;&amp;#151; The expected&#13;term of options represents the period that the Company&amp;#146;s stock-based awards are expected to be outstanding based on the simplified&#13;method, which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent&#13;remaining term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&amp;#160;&amp;#151; The&#13;Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable&#13;future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock&#13;options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <tpiv:PriorPeriodReclassifications contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Prior Period Reclassifications&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior period amounts that were&#13;combined in the December 31, 2013 consolidated financial statements have been reclassified for comparability with the December&#13;31, 2014 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;</tpiv:PriorPeriodReclassifications>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of certain of the Company&amp;#146;s&#13;financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost&#13;because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a&#13;recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values.&#13;Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets&#13;and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated&#13;by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets&#13;or liabilities. Financial Instruments and Concentration of Credit Risk.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of cash, accounts payable,&#13;and other current monetary liabilities approximate their carrying values due to the immediate or short-term maturity of these financial&#13;instruments. The Company&amp;#146;s operations and financing activities are conducted primarily in United States dollars, and as a&#13;result the Company is not subject to significant exposure to market risks from changes in foreign currency rates. Unless otherwise&#13;noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from assets and&#13;liabilities classified as financial instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Principles of Consolidation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements include the&#13;accounts of the Company and its wholly-owned subsidiaries GeneMax Pharmaceuticals Inc. (&amp;#147;GPI&amp;#148;) and GeneMax Pharmaceuticals&#13;Canada Inc. (&amp;#147;GPC&amp;#148;). All significant intercompany balances and transactions are eliminated upon consolidation. In the&#13;fourth quarter of fiscal 2014, the Company dissolved GPC and no longer has any Canadian subsidiary.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basis of Presentation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements are presented&#13;in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States&#13;of America (&amp;#147;GAAP&amp;#148;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Preparation of the Company&amp;#146;s financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and&#13;disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&amp;#146;s&#13;estimates and assumptions include deferred taxes and related tax balances and disclosures, determining the fair value of stock-based&#13;compensation and stock based transactions, the fair value of the components of the convertible notes payable and accrued liabilities.&#13;Matters impacting the Company&amp;#146;s ability to continue as a going concern and contingencies also involve the use of estimates&#13;and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities were not included in the diluted net&#13;loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;2,556,133&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;25,168&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;103,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;124,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;738,760&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Excluded potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;2,724,847&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;953,642&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounts Payable and Accrued Liabilities&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;December 31, 2014 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;December 31, 2013 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Trade accounts payable &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;620,826 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,450,083 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Share-settled debt&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,348,663&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Accrued liabilities &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;68,448 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;201,334 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Employee payroll and severance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;220,290 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Accrued interest &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,088 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;558,032 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;693,362 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;3,778,401&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The inputs utilized in the final mark to&#13;market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter ending June 30, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Total&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Dividend yield (per share)&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Strike price&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;1.027&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.88&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Volatility (annual)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Contractual term (years)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.06&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Fair value of Conversion Option at extinguishment&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;708,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;712,000 &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of quantitative information with&#13;respect to valuation methodology and significant unobservable inputs used for the Company&amp;#146;s common stock purchase warrants&#13;that are categorized within Level 3 of the fair value hierarchy for the years ended 2014 and 2013 is as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Share purchase warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.85 to 2.78&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.13% to 0.78%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;1.22 to 3.53&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.25% to 1.10%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;155.90% to 190.68%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets and liabilities measured&#13;at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &amp;#150; warrants&#13;and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2014 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2013&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents changes in Level 3 liabilities&#13;measured at fair value for the year ended December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 34%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 40%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&amp;#160;Derivative liability &amp;#150; conversion option &lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Derivative liability &amp;#150; warrants&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; January 1, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$868,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$977,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;811,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;206,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,096,000)&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,043,000)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$583,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$140,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Gain on settlement of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(714,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of conversion option liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;131,000&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(131,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 9,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="font-weight: normal"&gt;The&#13;following table summarizes the Company&amp;#146;s outstanding convertible note obligations:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-right: 1.8pt; text-align: right"&gt;&lt;b&gt;Stated&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;Principal Balance Outstanding&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Maturity Date&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: right"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Rate&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Conversion Terms&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;2/24/2011&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;2/24/2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30%; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 0.8pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 0.8pt; text-align: right"&gt;$ 980,858&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/4/2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/4/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;215,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/6/2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/6/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;30,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/12/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/12/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;27,500&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/20/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/20/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;20,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/15/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/15/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $12.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;340,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/20/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/20/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10,748&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/18/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/14/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;9.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $10.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;1/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $8.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;452,729&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;1/31/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $4.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;24,135&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;2/27/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;2/27/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;58,500&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;80,967&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;31,688&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $3.44&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;45,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/14/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/14/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $6.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;126,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/27/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/27/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;37,620&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;32,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/12/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/12/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $3.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;96,800&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/18/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;94,444&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/1/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/1/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;80,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/19/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;277,222&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;12/23/2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;6/23/2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;536,400&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;Total convertible notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;3,697,611&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;Unamortized note discount&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;(535,634)&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;&lt;b&gt;Total on Balance sheet&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: right"&gt;3,161,977&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s stock&#13;options as of December 31, 2014 and 2013 and changes during the years is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2012&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.05&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;5.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;4.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the status of the Company&amp;#146;s&#13;unvested options as of December 31, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;1,111&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Vested&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;(833)&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;278&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s share&#13;purchase warrants as of December 31, 2014 and changes during the year is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;149,452&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;25.85&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;2.76&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,546,132&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;1.30&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;4.23&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(36,167)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;40.00&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,659,417&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;1.83&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;4.15&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision (benefit) for&#13;the years ended December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 55%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 23%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 22%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Federal:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;State:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160; &lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,321,000&amp;#160; &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effects of temporary differences that&#13;give rise to significant portions of the deferred tax assets as of December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 53%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Ney operating loss carryforwards &lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;10,433,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,174,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Stock-based compensation&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,871,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ &amp;#160;&amp;#160;&amp;#160;1,866,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Technology licensing fee&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total deferred tax assets&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;12,471,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;11,207,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;(12,471,000)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(11,207,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <tpiv:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefit contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2014 and&#13;2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit)&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 21%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;U.S. federal statutory rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;(10,449,000)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;(1,881,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Permanent differences&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- Non-cash loss on extinguishment of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;9,122,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;893,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-Other permanent differences&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;62,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(334,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,322,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefit>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.50</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.40</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.00</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.75</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.25</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P6M</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="Shares" decimals="INF">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="Shares" decimals="INF">7320000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USD" decimals="0">950000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USD" decimals="0">1250000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USD" decimals="0">50000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USD" decimals="0">214000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="Pure" decimals="INF">0.025</tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents>
    <tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="Pure" decimals="INF">0.05</tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents>
    <tpiv:NumberOfPostconsolidatedSharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">112000</tpiv:NumberOfPostconsolidatedSharesOfCommonStock>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">362000</us-gaap:LossContingencyDamagesPaidValue>
    <tpiv:BondPayment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">100000</tpiv:BondPayment>
    <tpiv:AmountPaidByConsultant contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">196204</tpiv:AmountPaidByConsultant>
    <tpiv:InterestPaidByConsultant contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.09</tpiv:InterestPaidByConsultant>
    <us-gaap:LegalFees contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">210255</us-gaap:LegalFees>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">196204</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <tpiv:JudgmentAwardAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">51000</tpiv:JudgmentAwardAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1881000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10449000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">893000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">9122000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <tpiv:PermanentDifferencesotherPermanentDifferences contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-334000</tpiv:PermanentDifferencesotherPermanentDifferences>
    <tpiv:PermanentDifferencesotherPermanentDifferences contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">62000</tpiv:PermanentDifferencesotherPermanentDifferences>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26982085</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">30686428</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">149452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2659417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-01-01to2013-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2546132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-36167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">25.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">40.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P2Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2013-01-01to2013-12-31">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P4Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tpiv:Exercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P0Y</tpiv:Exercised>
    <tpiv:ExtinguishedOrExpired contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P0Y</tpiv:ExtinguishedOrExpired>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2013-01-01to2013-12-31">P5Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31">P4Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P4Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="From2013-01-01to2013-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <tpiv:Cancelledforfeited contextRef="From2013-01-01to2013-12-31">P0Y</tpiv:Cancelledforfeited>
    <tpiv:Cancelledforfeited contextRef="From2014-01-01to2014-12-31">P0Y</tpiv:Cancelledforfeited>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1111</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">278</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">-833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <tpiv:NumberOfOutstandingSharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">100</tpiv:NumberOfOutstandingSharesOfCommonStock>
    <tpiv:NumberOfOutstandingSharesOfCommonStock contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">5250</tpiv:NumberOfOutstandingSharesOfCommonStock>
    <tpiv:CommonStockAuthorizedFirst contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">150000000</tpiv:CommonStockAuthorizedFirst>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">94340</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">1.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">P4Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">1.503</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">1.566</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">1.503</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0163</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">0.014</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">0.0166</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">700000</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:PartnersCapitalAccountExchangesAndConversions contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">24900000</us-gaap:PartnersCapitalAccountExchangesAndConversions>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">31000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <tpiv:SharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1400000</tpiv:SharesOfCommonStock>
    <us-gaap:MinorityInterestPreferredStockAmount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">500000</us-gaap:MinorityInterestPreferredStockAmount>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">418000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebt contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4700000</us-gaap:ConvertibleDebt>
    <us-gaap:LicenseCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">91000</us-gaap:LicenseCosts>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">953642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">2724847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <tpiv:ConvertibleNotes contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">738760</tpiv:ConvertibleNotes>
    <tpiv:ConvertibleNotes contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">124284</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">103284</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">25168</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">2556133</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockOptions contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">65430</tpiv:CommonStockOptions>
    <tpiv:CommonStockOptions contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">65430</tpiv:CommonStockOptions>
    <tpiv:NumberOfOvarianCancerPatients contextRef="From2014-01-01to2014-12-31" unitRef="Patients" decimals="INF">30000</tpiv:NumberOfOvarianCancerPatients>
    <tpiv:PercentageOfBreastCancers contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.50</tpiv:PercentageOfBreastCancers>
    <tpiv:PercentageOfofOvarianCancers contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.95</tpiv:PercentageOfofOvarianCancers>
    <tpiv:LoansPayableDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;/font&gt;NOTE&#13;7:&amp;#9;LOANS PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As at December 31, 2014, there were unsecured&#13;loan payable in the amount of $nil (December 31, 2013 - $42,200). During the year ended December 31, 2014, investors converted&#13;$37,000 and a related party converted $5,200 of the loan into preferred stock which was immediately converted into common stock&#13;(see note 6).&lt;/p&gt;</tpiv:LoansPayableDisclosureTextBlock>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;Note&#13;6:&amp;#9;CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the Company&amp;#146;s outstanding&#13;convertible note obligations:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-right: 1.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stated&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal Balance Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Rate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conversion Terms&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/24/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/24/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30%; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 980,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/4/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/4/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/6/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/6/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/12/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/12/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;27,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/20/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/20/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/15/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/15/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/20/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/20/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/18/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/14/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $10.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $8.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;452,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1/31/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $4.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;24,135&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/27/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/27/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,967&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,688&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $3.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/14/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/14/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $6.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;126,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/27/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/27/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,620&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/12/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/12/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/18/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94,444&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/1/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/1/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;277,222&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/23/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/23/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;536,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,697,611&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unamortized note discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(535,634)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total on Balance sheet&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,161,977&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Issuance of Convertible Preferred Stock&#13;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year the Company issued $418,000&#13;of convertible notes. The notes carried no interest rate and were converted shortly thereafter (see Extinguishment loss) into preferred&#13;stock and immediately into common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Debt converted to Preferred Stock and&#13;immediately converted into common stock &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year, note holders that included&#13;Convertible notes, Loans payable, Promissory notes-related party &amp;#38; Due to related party exchanged approximately $4.7 million&#13;of debt and $0.5 million of accrued interest for shares of preferred stock, which was immediately converted into 14.0 million shares&#13;of common stock with a fair value of approximately $31 million. The total loss on extinguishment associated with the note conversions&#13;was $24.9 million, which includes the extinguishment of the derivative liability &amp;#150; conversion option of $0.7 million.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;10:&amp;#9;Capital Stock&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock Split and increase in authorized shares&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2014, the Company completed&#13;a reverse stock split thereby issuing 1 new share for each 100 outstanding shares of the Company&amp;#146;s common stock and amended&#13;the Company&amp;#146;s Articles of Incorporation to increase the authorized shares of common stock from 150,000,000 shares of common&#13;stock to 500,000,000 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Share Capital&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 6, 2014, the Company designated&#13;1,250,000 Series A preferred shares par value $0.001 (&amp;#147;Series A Convertible Preferred Stock&amp;#148;). Each share of Series&#13;A Convertible Preferred Stock automatically converted into five (5) shares of the Company&amp;#146;s common stock upon the occurrence&#13;of the 1:100 reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2014, the Company created&#13;a class of up to 1,500,000 preferred shares, par value $0.001, called Series B convertible preferred stock (&amp;#147;Series B Convertible&#13;Preferred Stock&amp;#148;). The terms of the Series B Convertible Preferred Stock are:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;rank pari passu to the common stock with respect to rights on liquidation, winding up and dissolution;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;have no dividend rights except as may be declared by the Board in its sole and absolute discretion;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 17.85pt"&gt;&lt;/td&gt;&lt;td style="width: 17.85pt"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;shall have the right to cast one thousand (1,000) votes for each share held of record on all matters&#13;submitted to a vote of holders of the Corporation&amp;#146;s common stock; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;shall automatically convert into seven (7) shares of common upon the occurrence of a 1:100 reverse&#13;stock split.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All prior period share transactions included&#13;in the Company&amp;#146;s stock transactions and balances have been retroactively restated for the reverse stock splits described&#13;above. There are no shares outstanding under preferred shares as of December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2014 Share Transactions&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Consulting services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;the Company issued in aggregate 811,000 shares of common stock in exchange for consulting services for which performance was complete.&#13;The fair value of the common stock recognized was approximately $954,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Private placements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;the Company entered into a Securities Purchase Agreement with a single institutional investor for the sale of 1,886,792 units at&#13;a purchase price of $1.06 per unit, for a total purchase price of $1,836,000, net of finders&amp;#146; fee of $164,000. Each unit&#13;consists of one common share and one share purchase warrant exercisable at $1.17 for a period of 5 years. The Company also issued&#13;94,340 placement agent share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise&#13;price of $1.325 per share for an exercise period of up to five years from the issuance date. The warrants were included within&#13;equity. The fair value of these warrants was determined to be $111,000, using the Black-Scholes Option Pricing Model with a contractual&#13;term of 5 years, a risk free interest rate of 1.66%, a dividend yield of 0%, and an expected volatility of 150.3%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;the Company received subscription proceeds of $265,000 for 265,000 units. Each unit consists of one share of common stock and one&#13;share purchase warrant exercisable at $2.50 for a period of 3 years. The Company also issued 5,250 shares of common stock as finders&amp;#146;&#13;fee relating to the subscription proceeds. The fair value of the common stock was determined to be $5,250.&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock Compensation Plan&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 14, 2009, the Company adopted&#13;the 2009 Stock Incentive Plan (the &amp;#147;2009 Plan&amp;#148;) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows&#13;for the issuance of up to 100,000 common shares. Options granted under the Plan shall be at prices and for terms as determined&#13;by the Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The expensed portion of the value of the&#13;granted and vested options during the year ended December 31, 2014 was $15,000 (2013 - $132,093) which was recorded as stock based&#13;consulting and management fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share purchase options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s stock&#13;options as of December 31, 2014 and 2013 and changes during the years is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2012&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.05&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;5.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;4.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2014, the intrinsic value&#13;of the vested options was equal to $nil (2013 - $nil).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the status of the Company&amp;#146;s&#13;unvested options as of December 31, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;1,111&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Vested&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;(833)&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;278&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share Purchase Warrants &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September, 2014, the Company issued&#13;100,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $1.15&#13;per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a service agreement.&#13;The fair value of these warrants was determined to be $105,000, using the Black-Scholes Option Pricing Model with a contractual&#13;term of 5 years, a risk free interest rate of 1.63%, a dividend yield of 0%, and an annual volatility of 150.18%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March, 2014, the Company issued 100,000&#13;share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $4.00 per share&#13;for an exercise period of up to four years from the issuance date. The warrants were issued pursuant to a technology option agreement.&#13;The fair value of these warrants was determined to be $303,000 and was recorded in general and administrative expenses. The weighted&#13;average assumptions used for the Black-Scholes option-pricing model to value these warrants were: volatility of 156.6%, risk free&#13;rate of 1.4%, term of 4 years and dividend rate of 0%. The Company used the Black-Scholes option-pricing model as the resultant&#13;fair value is not significantly different than the Monte Carlo option pricing model. In August 2014, the Company repriced the 100,000&#13;warrants by reducing the exercise price from $4.00 to $1.06. As a result, the Company recorded incremental fair value of $14,000&#13;during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s share&#13;purchase warrants as of December 31, 2014 and changes during the year is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;149,452&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;25.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.76&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,546,132&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.23&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,167)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 20.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 23.5pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,659,417&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 20.4pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&amp;#160;&amp;#160;1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 23.5pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.15&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;NOTE 11: INCOME TAXES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision (benefit) for&#13;the years ended December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 55%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 23%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 22%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Federal:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;State:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160; &lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,321,000&amp;#160; &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;br /&gt;&#13;The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2014&#13;and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 53%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Ney operating loss carryforwards &lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;10,433,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,174,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Stock-based compensation&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,871,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ &amp;#160;&amp;#160;&amp;#160;1,866,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Technology licensing fee&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total deferred tax assets&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;12,471,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;11,207,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;(12,471,000)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(11,207,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assesses the likelihood that&#13;deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based&#13;upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will&#13;not be realized and has established a full valuation allowance for the years ended December 31, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has not filed U.S tax returns&#13;since inception, but is in the process of filing tax returns for the years ended December 31, 2014, 2013, 2012, 2011, 2010, and&#13;2009. The Net operating losses (&amp;#147;NOLs&amp;#148;) will not be available to reduce future taxable income until the returns are&#13;filed. Assuming these returns are filed, as of December 31, 2014 and 2013, the Company has approximately $30,686,428 and $26,982,085,&#13;respectively, of federal NOLs that may be available to offset future taxable income, if any. The federal net operating loss carryforwards,&#13;if not utilized, will expire beginning in 2023.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has also not filed any Canadian&#13;tax returns for GPC, which was dissolved in the fourth quarter of fiscal year 2014. The Company could be subject to fines and penalties&#13;for not filing the tax returns. The Company does not know the quantum of such fines and penalties, if any, and no liabilities have&#13;been accrued in the fiscal year 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with Section 382 of the Internal&#13;Revenue code, the usage of the Company&amp;#146;s net operating loss carryforwards may be limited in the event of a change in ownership.&#13;A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.&amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2014 and&#13;2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit)&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 21%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;U.S. federal statutory rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;(10,449,000)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;(1,881,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Permanent differences&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- Non-cash loss on extinguishment of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;9,122,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;893,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-Other permanent differences&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;62,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(334,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,322,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 740 prescribes a recognition threshold&#13;and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken&#13;in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination&#13;by taxing authorities. As of December 31, 2014 and 2013, there were no unrecognized tax benefits. The Company recognizes accrued&#13;interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31,&#13;2014 and 2013. The Company is currently not aware of any issues under review that could result in significant payments, accruals&#13;or material deviation from its position in the next year.&lt;font style="text-transform: uppercase"&gt; &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">5200</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">708000</tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions>
    <tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15000</tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">14000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">303000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">111000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:ReceivedSubscriptionProceeds1 contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">1836000</tpiv:ReceivedSubscriptionProceeds1>
    <tpiv:ExcercisePriceOfWarrant contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.17</tpiv:ExcercisePriceOfWarrant>
    <tpiv:ExercisePriceOfPlacementShares contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.325</tpiv:ExercisePriceOfPlacementShares>
    <us-gaap:ProceedsFromFeesReceived contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">265000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2014-01-01to2014-03-31" unitRef="USDPShares" decimals="INF">1.027</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2014-04-01to2014-06-30" unitRef="USDPShares" decimals="INF">0.88</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
</xbrli:xbrl>
